In a nutshell This review looked at whether medications similar to the GLP-1 hormone can improve liver health for people with type 2 diabetes (T2D) and fatty liver disease. It found that these medications can improve liver health and reduce fat in the liver. Some background As many as 60% of people with T2D also develop non-alcoholic fatty liver...
Read More
In a nutshell This study compared treatments for fatty liver disease in patients with type 2 diabetes (T2D). They found that liraglutide (Victoza) reduced liver fat significantly, improved liver function, and led to weight loss and better blood sugar control. Some background Half of the patients with T2D can have liver disease...
Read More
In a nutshell This trial is examining the effectiveness of LIK006 in obese patients with non-alcoholic steatohepatitis (NASH; fatty liver not caused by alcohol consumption). The main outcomes to be measured will be the change in liver enzymes and liver and body fat at week 12. The details Nonalcoholic steatohepatitis (NASH) is...
Read MoreIn a nutshell The aim of this study was to investigate the effect of canagliflozin (Invokana) on insulin secretion and action along with changes in liver fat deposits and weight loss in patients with type 2 diabetes (T2D). The main finding of the study was that canagliflozin improved insulin secretion and usage, increased weight loss and...
Read More
In a nutshell This review summarized the treatment options available to type 2 diabetes patients with non-alcoholic fatty liver disease (NAFLD). This review considers current treatment options and possible future treatments. Some background Type 2 diabetes (T2D) can lead to multiple complications over time. NAFLD is increasing in patients...
Read MoreIn a nutshell The authors aimed to determine the effect of liraglutide (Victoza) on liver fat content in patients with uncontrolled type 2 diabetes. The authors concluded that six months treatment with liraglutide significantly reduced liver fat content in patients with uncontrolled type 2 diabetes by reducing body weight. Some...
Read MoreIn a nutshell The authors aimed to determine the effectiveness and safety of long-term pioglitazone (Actos) treatment in patients with nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes. The authors concluded that long-term pioglitazone treatment is safe and effective in patients with NASH and prediabetes or type 2...
Read More
In a nutshell This study examined the metabolic effect of NASH in patients with type 2 diabetes. The authors concluded that NAFLD in patients with type 2 diabetes is associated with worse metabolic effects. Some background Altered metabolism occurs in patients with type 2 diabetes (T2D). These effects include a reduction in the ability of insulin...
Read More
In a nutshell This study examined whether non-alcoholic fatty liver disease increases the risk of diabetic kidney disease. Some background Long-term hyperglycemia (high blood glucose levels) can result in many complications for patients with type 2 diabetes (T2D). Diabetic nephropathy is a progressive kidney disease whereby the blood vessels...
Read More
In a nutshell This review analyzed different studies that evaluated the effect of antihypertensive agents (blood pressure-lowering drugs) on the onset and progress of diabetic kidney disease (DKD). Some background Diabetes mellitus (DM) is a condition which increases blood sugar levels in the body. Cardiovascular diseases (CVD), such as...
Read More
